Cyprus vs United Arab Emirates: Share of E. coli infections resistant to cephalosporins
Cyprus
40.5%
in 2022
United Arab Emirates
52.4%
in 2022
Cyprus rank
20th
United Arab Emirates rank
17th
Share of E. coli infections resistant to cephalosporins over time
- Cyprus
- United Arab Emirates
How they compare
United Arab Emirates currently reports 52.4% against 40.5% in Cyprus, a difference of 11.9%.
That makes United Arab Emirates's figure about 1.3 times Cyprus's.
Across all 6 years both countries report, United Arab Emirates has been ahead every year.
Cyprus ranks 20th and United Arab Emirates ranks 17th of 46 countries.
United Arab Emirates has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Cyprus | United Arab Emirates | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 29.2% | 47.5% | 18.4% | United Arab Emirates |
| 2020s | 44.4% | 52.7% | 8.3% | United Arab Emirates |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher share of e. coli infections resistant to cephalosporins, Cyprus or United Arab Emirates?
- United Arab Emirates, at 52.4% against 40.5% in Cyprus as of 2022.
- What is the difference in share of e. coli infections resistant to cephalosporins between Cyprus and United Arab Emirates?
- 11.9%, with United Arab Emirates ahead.
- How many years of comparable data are there for Cyprus and United Arab Emirates?
- 6 years are reported by both, from 2017 to 2022.
- How do Cyprus and United Arab Emirates rank globally for share of e. coli infections resistant to cephalosporins?
- Cyprus ranks 20th and United Arab Emirates ranks 17th of 46 countries.
- Where does this data come from?
- World Health Organization – processed by Our World in Data, published as Share of E. coli infections resistant to cephalosporins. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Percentage of bloodstream infection due to Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested (%).